Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NEPTUNE: Brepocitinib in Non-Infectious Uveitis
NCT05523765Phase 2Completed
- Sponsor
- Priovant Therapeutics
- Start
- Nov 2022
- Primary completion
- Jul 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of brepocitinib in non-infectious intermediate uveitis, non-infectious posterior uveitis (NIPU), non-infectious panuveitis (NIU), sponsored by Priovant Therapeutics. Started Nov 2022; status: completed.
02
Drugs
brepocitinib
03
Conditions
non-infectious intermediate uveitisnon-infectious posterior uveitis (NIPU)non-infectious panuveitis (NIU)
Beyond the preview
Go deeper on NCT05523765.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05523765.